Biopharmaceutical company focused on targeted protein modulation for cancer and immune disorders.
Nurix Therapeutics, Inc. is a pioneering biopharmaceutical company dedicated to advancing the field of small molecule therapies for cancer and immune disorders. The company focuses on discovering, developing, and commercializing innovative treatments that target critical pathways involved in disease progression.
Among its promising pipeline, Nurix Therapeutics is developing NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader designed to address relapsed or refractory B-cell malignancies. Similarly, NX-5948, another orally bioavailable BTK degrader, targets both B-cell malignancies and autoimmune diseases. Additionally, the company is advancing NX-1607, an orally available inhibitor of Casitas B-lineage lymphoma proto-oncogene-B (CBL-B), with applications in immuno-oncology.
Innovative approaches include NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, and DeTIL-0255, currently in Phase 1 clinical trials for treating gynecologic cancers such as ovarian, endometrial, and cervical cancer. Nurix Therapeutics collaborates strategically with industry leaders like Gilead Sciences, Inc. and Sanofi S.A. to accelerate the development of therapies for challenging diseases.
Founded in 2009 and headquartered in San Francisco, California, Nurix Therapeutics, Inc. was originally known as Nurix Inc. before rebranding in October 2018. The company continues to drive innovation in biopharmaceuticals, leveraging its expertise to address critical unmet medical needs in oncology and immunology.